Fibromyalgia, mood disorders, and intense creative energy: A1AT polymorphisms are not always silent

NeuroToxicology

Volumn 33, Issue 6, 2012, Pages 1454-1472

  Schmechel, Donald E ^a,b   Edwards, Christopher L ^b  

^a The Falls Neurological and Memory Center   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alpha 1 antitrypsin extended phenotype; Dementia; Intense creative energy; Juvenile rheumatoid arthritis fibromyalgia; PTSD mood disorders

Indexed keywords

APOLIPOPROTEIN E4; METHYLENETETRAHYDROFOLATE DEHYDROGENASE;

A1AT GENE; ADOLESCENT; ADULT; AGED; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; CASE CONTROL STUDY; FEMALE; FIBROMYALGIA; GENE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HETEROZYGOTE; HOMOZYGOTE; HUMAN; JUVENILE RHEUMATOID ARTHRITIS; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MEDICAL HISTORY; MOOD DISORDER; PHENOTYPE; POSTTRAUMATIC STRESS DISORDER; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGIC TEST; RETROSPECTIVE STUDY;

AFFECT; AGED; AGED, 80 AND OVER; ALPHA 1-ANTITRYPSIN; ANALYSIS OF VARIANCE; ARTHRITIS, JUVENILE RHEUMATOID; CHI-SQUARE DISTRIBUTION; CREATIVITY; ENVIRONMENTAL POLLUTANTS; FEMALE; FIBROMYALGIA; GENE FREQUENCY; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MOOD DISORDERS; NEUROTOXICITY SYNDROMES; NORTH CAROLINA; OCCUPATIONAL EXPOSURE; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84871720261     PISSN: 0161813X     EISSN: 18729711     Source Type: Journal    
DOI: 10.1016/j.neuro.2012.03.001     Document Type: Article

References (51)

1. Ablin J.N., Bar-Shira A., Yaron M., Orr-Urtreger A. Candidate-gene approach in fibromyalgia syndrome: association analysis of the genes encoding substance P receptor, dopamine transporter and alpha1-antitrypsin. Clin Exp Rheumatol 2009, 27(SEPTEMBER-October (5 Suppl. 56)):S33-S38.
2. Ahn K.H., Lyoo I.K., Lee H.K., Song I.C., Oh J.S., et al. White matter hyperintensities in subjects with bipolar disorder. Psychiatry Clin Neurosci 2004, 58(5):516-521.
3. Aldonyte R., Jansson L., Ljungberg O., Larsson S., Janciauskiene S. Polymerized alpha-antitrypsin is present on lung vascular endothelium. New insights into the biological significance of alpha-antitrypsin polymerisation. Histopathology 2004, 45(6):587-592.
4. Arnaud P., Galbraith R.M., Faulk W.P. Increased frequency of the MZ phenotype of alpha-1-protease inhibitor in juvenile chronic polyarthritis. J Clin Invest 1977, 60(6):1442-1444.
5. 1-antitrypsin deficiency. Chest 2010, 138(November (5)):1116-1124. [Epub 2010 July 15].
6. Bernspang E., Wollmer P., Sveger T., Piitulainen E. Lung function in 30-year old alpha-1-antitrypsin deficient individuals. Resp Med 2009, 103(6):861-865.
7. Billingsley G.D., Walter M.A., Hammond G.L., Cox D.W. Physical mapping of four serpin genes: alpha 1-antitrypsin, alpha 1-antichymotrypsin, corticosteroidbinding globulin, and protein C inhibitor, within a 280-kb region on chromosome 14q32.1. Am J Hum Genet 1993, 2:343-353.
8. Blanco I., Bustillo E.F., Rodriguez M.C. Distribution of alpha1-antitrypsin PI S and PI Z frequencies in countries outside Europe: a meta-analysis. Clin Genet 2001, 60(6):431-441.
9. Blanco I., Canto H., de Serres F.J., Fernandez-Bustillo E., Rodríguez M.C. Alpha1-antitrypsin replacement therapy controls fibromyalgia symptoms in 2 patients with PI ZZ alpha1-antitrypsin deficiency. J Rheumatol 2004, 31(October (10)):2082-2085.
10. Blanco L.E., de Serres F.J., Fernańdez-Bustillo E., Kassam D.A., Arbesú D., et al. Alpha1-Antitrypsin and fibromyalgia: new data in favour of the inflammatory hypothesis of fibromyalgia. Med Hypotheses 2005, 64(4):759-769.
11. Boomsma D.I., Frants R.R., Bank R.A., Martin N.G. Protease inhibitor (Pi) locus, fertility and twinning. Hum Genet 1992, 89(May (3)):329-332.
12. Brambilla P., Glahn D.C., Balestrieri M., Soares J.C. Magnetic resonance findings in bipolar disorder. Psychiatric Clin N Am 2005, 28(2):443-467.
13. Cuffe S.P., Addy C.L., Garrison C.Z., Waller J.L., Jackson K.L., McKeown R.E., et al. Prevalence of PTSD in a community sample of older adolescents. J Am Acad Child Adolesc Psychiatry 1998, 37(2):147-154.
14. Dahl M., Tybjaerg-Hansen A., Sillesen H., Jensen G., Steffensen R., Nordestgaard B.G. Blood pressure, risk of ischemic cerebrovascular and ischemic heart disease, and longevity in alpha(1)-antitrypsin deficiency: the Copenhagen City Heart Study. Circulation 2003, 107(5):747-752.
15. de Serres F.J. Worldwide racial and ethnic distribution of alpha1-antitrypsin deficiency: summary of an analysis of published genetic epidemiologic surveys. Chest 2002, 122(5):1818-1829.
16. de Serres F.J. Alpha-1 antitrypsin deficiency is not a rare disease but a disease that is rarely diagnosed. Environ Health Perspect 2003, 111(16):1851-1854.
17. de Serres F.J., Blanco I., Fernandez-Bustillo E. Health implications of alpha1-antitrypsin deficiency in Sub-Sahara African countries and their emigrants in Europe and the New World. Genet Med 2005, 7(3):175-184.
18. Eden E., Strange C., Holladay B., Xie L. Asthma and allergy in alpha-1 antitrypsin deficiency. Respir Med 2006, 100(8):1384-1391.
19. Gadiyaram V.K., Khan M.A., Hogan T., Altaha R., Crowell E., et al. Significance of MTHFR gene mutation with normal homocysteine level in vascular events. J Clin Oncol 2009, 27.
20. Goodwin R.D., Fischer M.E., Goldberg J. A twin study of post-traumatic stress disorder symptoms and asthma. Am J Respir Crit Care Med 2007, 176(November (10)):983-987. [Epub 2007 August 16].
21. Graziadei I., Weiss G., Egger C., Niederwieser D., Patsch J.R., Vogel W. Modulation of iron metabolism in monocytic THP-1 cells and cultured human monocytes by the acute-phase protein alpha1-antitrypsin. Exp Hematol 1998, 26(11):1053-1060.
22. Graziadei I., Weiss G., Bohm A., Werner-Felmayer G., Vogel W. Unidirectional upregulation of the synthesis of the major iron proteins, transferrin-receptor and ferritin, in HepG2 cells by the acute-phase protein alpha1-antitrypsin. J Hepatol 1997, 27(4):716-725.
23. Haznedar M.M., Roversi F., Pallanti S., Baldini-Rossi N., Schnur D.B., et al. Fronto-thalamo-striatal gray and white matter volumes and anisotropy of their connections in bipolar spectrum illnesses. Biol Psychiatry 2005, 57(7):733-742.
24. Hersh C.P., Dahl M., Ly N.P., Berkey C.S., Nordestgaard B.G., Silverman E.K. Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis. Thorax 2004, 59(10):843-849.
25. Hidvegi T., Ewing M., Hale P., Dippold C., Beckett C., Kemp C., et al. An autophagy-enhancing drug promotes degradation of mutant alpha-1-antitrypsin Z and reduces hepatic fibrosis. Science 2010, 329:229-232.
26. Jamison K.R. Touched with fire: manic-depressive illness and the artistic temperament 1993, Free Press, Ontario.
27. Kato K., Sullivan P.F., Evengard B., Pedersen N.L. Importance of genetic influences on chronic widespread pain. Arthritis Rheum 2006, 54:1682-1686.
28. Kawashiri M., Kajinami K., Nohara A., Yagi K., Inazu A., et al. Effect of common methylenetetrahydrofolate reductase gene mutation on coronary artery disease in familial hypercholesterolemia. Am J Cardiol 2000, 86(8):840-845.
29. Knopman D.S., et al. Practice parameter: diagnosis of dementia (an evidencebased review). Report of the Quality Standards Committee of the American Academy of Neurology. Neurology 2001, 56:1143-1153.
30. Lieberman J., Borhani N.O., Feinleib M. Twinning as a heterozygous advantage for alpha1-antitrypsin deficiency. Prog Clin Biol Res 1978, 24(Pt B):45-54.
31. Limer K.L., Nicholl B.I., Thomson W., McBeth J. Exploring the genetic susceptibility of chronic widespread pain: the tender points in genetic association studies. Rheumatology 2008, 47(5):572-577.
32. Lomas D.A. The selective advantage of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2006, 173(May (10)):1072-1077.
33. Maletic V., Raison C.L. Neurobiology of depression, fibromyalgia and neuropathic pain. Front Biosci 2009, 14(June):5291-5338.
34. Markusen A. The artistic dividend revisited 2004, Hubert Institute of Public Affairs, Minneapolis.
35. Mesulam M.M. Primary progressive aphasia. Ann Neurol 2001, 49:425-432.
36. McGee D., Schwarz L., McClure R., Peterka L., Rouhani F., Brantly M., et al. Is PiSS alpha-1 antitrypsin deficiency associated with disease?. Pulm Med 2010, 570679. [Epub 2010 June 28].
37. Mulgrew A.T., Taggart C., Lawless M.W., Green C.M., Brantly M.L., O'Neill S.J., et al. Z alpha-1-antitrypsin polymerizes in the lung and serves as a neutrophil chemoattractant. Chest 2004, 125(5):1607-1609.
38. Parfrey H., Mahadeva R., Lomas D.A. Alpha(1)-antitrypsin deficiency, liver disease and emphysema. Int J Biochem Cell Biol 2003, 35(7):1009-1014.
39. Perlmutter D.H. Liver injury in alpha1-antitrypsin deficiency: an aggregated protein induces mitochondrial injury. J Clin Investig 2002, 110(11):1579-1583.
40. Perrot S., Vicaut E., Servant D., Ravaud P. Prevalence of fibromyalgia in France: a multi-step study research combining national screening and clinical confirmation: the DEFI study (Determination of Epidemiology of FIbromyalgia). BMC Musculoskelet Disord 2011, 12(October):224.
41. Petersen R.C., et al. Practice parameter: early detection of mild dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Committee of the American Academy of Neurology. Neurology 2001, 56:1133-1142.
42. Regev A., Guaqueta C., Molina E.G., Conrad A., Mishra V., Brantly M.L., et al. Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? Interim results of a large case-control study. J Pediatr Gastroenterol Nutr 2006, 43(July (Suppl. 1)):S30-S35.
43. Rogalski E., Johnson N., Weintraub S., Mesulam M. Increased frequency of learning disability in patients with primary progressive aphasia and their first-degree relatives. Arch Neurol 2008, 65(February (2)):244-248.
44. Russo AJ, Neville L, Wroge C. Low serum alpha-1 antitrypsin (AAT) in family members of individuals with autism correlates with PiMZ genotype Biomarker Insights. 2009;4:45-56.
45. Schmechel D.E., Browndyke J., Ghio A. Strategies for dissecting genetic-environmental interactions in neurodegenerative disorders. Neurotoxicology 2006, 27(SEPTEMBER (5)):637-657.
46. Schmechel D.E. Art, alpha-1-antitrypsin polymorphisms and intense creative energy: blessing or curse?. Neurotoxicology 2007, 28(5):899-914.
47. Schubert K., von Bonnsdorf H., Burke M., Ahlert I., Braun S., Berner R., et al. A comprehensive candidate gene study on bronchial asthma and juvenile idiopathic arthritis. Dis Markers 2006, 22(3):127-132.
48. Scott B.B., Egner W. Does alpha1-antitrypsin phenotype PiMZ increase the risk of fibrosis in liver disease due to hepatitis C virus infection?. Eur J Gastroenterol Hepatol 2006, 18(5):521-523.
49. Schäfer I., Fisher H.L. Childhood trauma and posttraumatic stress disorder in patients with psychosis: clinical challenges and emerging treatments. Curr Opin Psychiatry 2011, 24(November (6)):514-518.
50. Talmud P.J., Martin S., Steiner G., Flavell D.M., Whitehouse D.B., et al. Diabetes Atherosclerosis Intervention Study Investigators Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene. Arteriosc Thromb Vasc Biol 2003, 23(4):644-649.
51. Wilson P.W.F. Homocysteine and coronary heart disease: how great is the hazard?. JAMA 2002, 288(16):2042-2043.